332 related articles for article (PubMed ID: 16731829)
1. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms.
Okada T; Wada J; Hida K; Eguchi J; Hashimoto I; Baba M; Yasuhara A; Shikata K; Makino H
Diabetes; 2006 Jun; 55(6):1666-77. PubMed ID: 16731829
[TBL] [Abstract][Full Text] [Related]
2. Galectin-9 inhibits glomerular hypertrophy in db/db diabetic mice via cell-cycle-dependent mechanisms.
Baba M; Wada J; Eguchi J; Hashimoto I; Okada T; Yasuhara A; Shikata K; Kanwar YS; Makino H
J Am Soc Nephrol; 2005 Nov; 16(11):3222-34. PubMed ID: 16177004
[TBL] [Abstract][Full Text] [Related]
3. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.
Ko GJ; Kang YS; Han SY; Lee MH; Song HK; Han KH; Kim HK; Han JY; Cha DR
Nephrol Dial Transplant; 2008 Sep; 23(9):2750-60. PubMed ID: 18388116
[TBL] [Abstract][Full Text] [Related]
4. Advanced glycation end-products induce cell cycle arrest and hypertrophy in podocytes.
Rüster C; Bondeva T; Franke S; Förster M; Wolf G
Nephrol Dial Transplant; 2008 Jul; 23(7):2179-91. PubMed ID: 18344241
[TBL] [Abstract][Full Text] [Related]
5. The effect of high glucose and PPAR-gamma agonists on PPAR-gamma expression and function in HK-2 cells.
Panchapakesan U; Pollock CA; Chen XM
Am J Physiol Renal Physiol; 2004 Sep; 287(3):F528-34. PubMed ID: 15113752
[TBL] [Abstract][Full Text] [Related]
6. Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts.
Zafiriou S; Stanners SR; Saad S; Polhill TS; Poronnik P; Pollock CA
J Am Soc Nephrol; 2005 Mar; 16(3):638-45. PubMed ID: 15689403
[TBL] [Abstract][Full Text] [Related]
7. Parathyroid hormone-related protein induces hypertrophy in podocytes via TGF-beta(1) and p27(Kip1): implications for diabetic nephropathy.
Romero M; Ortega A; Izquierdo A; López-Luna P; Bosch RJ
Nephrol Dial Transplant; 2010 Aug; 25(8):2447-57. PubMed ID: 20200004
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptor-δ activation ameliorates albuminuria by preventing nephrin loss and restoring podocyte integrity in type 2 diabetes.
Lee EY; Kim GT; Hyun M; Kim S; Seok S; Choi R; Lee MY; Chung CH
Nephrol Dial Transplant; 2012 Nov; 27(11):4069-79. PubMed ID: 22892126
[TBL] [Abstract][Full Text] [Related]
9. Troglitazone inhibits synthesis of transforming growth factor-beta1 and reduces matrix production in human peritoneal mesothelial cells.
Peng Y; Liu H; Liu F; Liu Y; Li J; Chen X
Nephrology (Carlton); 2006 Dec; 11(6):516-23. PubMed ID: 17199790
[TBL] [Abstract][Full Text] [Related]
10. PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse.
Calkin AC; Giunti S; Jandeleit-Dahm KA; Allen TJ; Cooper ME; Thomas MC
Nephrol Dial Transplant; 2006 Sep; 21(9):2399-405. PubMed ID: 16720596
[TBL] [Abstract][Full Text] [Related]
11. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
Lin MS; Chen WC; Bai X; Wang YD
J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice.
Cha DR; Zhang X; Zhang Y; Wu J; Su D; Han JY; Fang X; Yu B; Breyer MD; Guan Y
Diabetes; 2007 Aug; 56(8):2036-45. PubMed ID: 17536062
[TBL] [Abstract][Full Text] [Related]
13. Correction of protein kinase C activity and macrophage migration in peripheral nerve by pioglitazone, peroxisome proliferator activated-gamma-ligand, in insulin-deficient diabetic rats.
Yamagishi S; Ogasawara S; Mizukami H; Yajima N; Wada R; Sugawara A; Yagihashi S
J Neurochem; 2008 Jan; 104(2):491-9. PubMed ID: 17995925
[TBL] [Abstract][Full Text] [Related]
14. p27(Kip1) Knockout mice are protected from diabetic nephropathy: evidence for p27(Kip1) haplotype insufficiency.
Wolf G; Schanze A; Stahl RA; Shankland SJ; Amann K
Kidney Int; 2005 Oct; 68(4):1583-9. PubMed ID: 16164635
[TBL] [Abstract][Full Text] [Related]
15. Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy.
Katavetin P; Eiam-Ong S; Suwanwalaikorn S
J Med Assoc Thai; 2006 Feb; 89(2):170-7. PubMed ID: 16579002
[TBL] [Abstract][Full Text] [Related]
16. Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-beta type II receptor.
Russo LM; del Re E; Brown D; Lin HY
Diabetes; 2007 Feb; 56(2):380-8. PubMed ID: 17259382
[TBL] [Abstract][Full Text] [Related]
17. Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-alpha or -gamma agonists in a type 2 diabetic animal model.
Kim SK; Zhao ZS; Lee YJ; Lee KE; Kang SM; Choi D; Lim SK; Chung N; Lee HC; Cha BS
Diabetes Metab Res Rev; 2003; 19(6):487-93. PubMed ID: 14648808
[TBL] [Abstract][Full Text] [Related]
18. The direct antioxidative and anti-inflammatory effects of peroxisome proliferator-activated receptors ligands are associated with the inhibition of angiotensin converting enzyme expression in streptozotocin-induced diabetic rat aorta.
Toba H; Miki S; Shimizu T; Yoshimura A; Inoue R; Sawai N; Tsukamoto R; Murakami M; Morita Y; Nakayama Y; Kobara M; Nakata T
Eur J Pharmacol; 2006 Nov; 549(1-3):124-32. PubMed ID: 16979161
[TBL] [Abstract][Full Text] [Related]
19. Effect of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on ischemia-reperfusion injury in rats.
Cao Z; Ye P; Long C; Chen K; Li X; Wang H
Pharmacology; 2007; 79(3):184-92. PubMed ID: 17356310
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptor alpha and gamma ligands inhibit the growth of human ovarian cancer.
Shigeto T; Yokoyama Y; Xin B; Mizunuma H
Oncol Rep; 2007 Oct; 18(4):833-40. PubMed ID: 17786343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]